-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
-
Summary
-
Entrada Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from Q3 2020 to Q2 2025.
- Entrada Therapeutics, Inc. Depreciation for the quarter ending June 30, 2025 was $1.1M, a 22.2% increase year-over-year.
- Entrada Therapeutics, Inc. Depreciation for the twelve months ending June 30, 2025 was $3.99M, a 16% increase year-over-year.
- Entrada Therapeutics, Inc. annual Depreciation for 2024 was $3.77M, a 32.8% increase from 2023.
- Entrada Therapeutics, Inc. annual Depreciation for 2023 was $2.84M, a 49.9% increase from 2022.
- Entrada Therapeutics, Inc. annual Depreciation for 2022 was $1.9M, a 69.7% increase from 2021.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)